Merck & Co. Submits FDA Application for Cervical Cancer Vaccine

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

U.S. Centers for Disease Control and Prevention • Medical News

Merck & Co. Submits FDA Application for Cervical Cancer Vaccine

December 6, 2005

On Dec. 1, Merck & Co. submitted an application for U.S. Food and Drug Administration approval of its cervical cancer vaccine Gardasil, which is engineered to protect against four types of human papillomavirus. Merck is seeking to get a priority review designation for Gardasil and said it expects FDA's decision in about two months. The drug company also plans this month to submit applications to license the vaccine in Europe and Asia.

Back to other news for December 6, 2005

Search the Newsroom archive

Excerpted from:
Wall Street Journal
12.06.05; Dow Jones Newswires

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.